Recombinant CD274 (Atezolizumab Biosimilar) anticorps

N° du produit ABIN7795089

L’anticorps Humanized Monoclonal anti-CD274 (Atezolizumab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter CD274 (Atezolizumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant CD274 (Atezolizumab Biosimilar) anticorps (ABIN7795089)

Antigène: CD274 (Atezolizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp CD274 (Atezolizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD274 (Atezolizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg

Attributs du produit: What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab. Atezolizumab lacks the N-glycosylation site in its Fc region by changing an aspartic acid into alanine at amino acid position 298 (amino acid position 297 according to EU nomenclature, N297A) in the heavy chain leading to minimized binding to FcγRs. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body's adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: Less than 0.5 EU/mg of protein as determined by LAL method

Immunogène: Human PD-L1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur CD274 (Atezolizumab Biosimilar)

Antigène: CD274 (Atezolizumab Biosimilar)

Autre désignation: Atezolizumab Biosimilar

Classe de substances: Biosimilar